Editor's Pick

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.

Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.

At the PAG conference, researchers said they are sequencing 100 tomato genomes in 100 days using Oxford Nanopore's PromethIon and a pipeline for maximizing SV diversity.

Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.

The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.

In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.

Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.

The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.

Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.

Pages

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.